15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Discoidin domain receptor 1 (DDR1) is a collagen-activated receptor tyrosine kinase extensively implicated in diseases such as cancer, atherosclerosis and fibrosis. Multiple preclinical studies, performed using either a gene deletion or a gene silencing approaches, have shown this receptor being a major driver target of fibrosis and glomerulosclerosis.

          Methods

          The present study investigated the role and relevance of DDR1 in human crescentic glomerulonephritis (GN). Detailed DDR1 expression was first characterized in detail in human GN biopsies using a novel selective anti-DDR1 antibody using immunohistochemistry. Subsequently the protective role of DDR1 was investigated using a highly selective, novel, small molecule inhibitor in a nephrotoxic serum (NTS) GN model in a prophylactic regime and in the NEP25 GN mouse model using a therapeutic intervention regime.

          Results

          DDR1 expression was shown to be mainly limited to renal epithelium. In humans, DDR1 is highly induced in injured podocytes, in bridging cells expressing both parietal epithelial cell (PEC) and podocyte markers and in a subset of PECs forming the cellular crescents in human GN. Pharmacological inhibition of DDR1 in NTS improved both renal function and histological parameters. These results, obtained using a prophylactic regime, were confirmed in the NEP25 GN mouse model using a therapeutic intervention regime. Gene expression analysis of NTS showed that pharmacological blockade of DDR1 specifically reverted fibrotic and inflammatory gene networks and modulated expression of the glomerular cell gene signature, further validating DDR1 as a major mediator of cell fate in podocytes and PECs.

          Conclusions

          Together, these results suggest that DDR1 inhibition might be an attractive and promising pharmacological intervention for the treatment of GN, predominantly by targeting the renal epithelium.

          Electronic supplementary material

          The online version of this article (10.1186/s12967-018-1524-5) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: not found
          • Article: not found

          Rapidly progressive crescentic glomerulonephritis.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Discoidin domain receptors in disease.

            Discoidin domain receptors, DDR1 and DDR2, lie at the intersection of two large receptor families, namely the extracellular matrix and tyrosine kinase receptors. As such, DDRs are uniquely positioned to function as sensors for extracellular matrix and to regulate a wide range of cell functions from migration and proliferation to cytokine secretion and extracellular matrix homeostasis/remodeling. While activation of DDRs by extracellular matrix collagens is required for normal development and tissue homeostasis, aberrant activation of these receptors following injury or in disease is detrimental. The availability of mice lacking DDRs has enabled us to identify key roles played by these receptors in disease initiation and progression. DDR1 promotes inflammation in atherosclerosis, lung fibrosis and kidney injury, while DDR2 contributes to osteoarthritis. Furthermore, both DDRs have been implicated in cancer progression. Yet the mechanisms whereby DDRs contribute to disease progression are poorly understood. In this review we highlight the mechanisms whereby DDRs regulate two important processes, namely inflammation and tissue fibrosis. In addition, we discuss the challenges of targeting DDRs in disease. Selective targeting of these receptors requires understanding of how they interact with and are activated by extracellular matrix, and whether their cellular function is dependent on or independent of receptor kinase activity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury.

              This study aimed to generate a mouse model of acquired glomerular sclerosis. A model system that allows induction of podocyte injury in a manner in which onset and severity can be controlled was designed. A transgenic mouse strain (NEP25) that expresses human CD25 selectively in podocytes was first generated. Injection of anti-Tac (Fv)-PE38 (LMB2), an immunotoxin with specific binding to human CD25, induced progressive nonselective proteinuria, ascites, and edema in NEP25 mice. Podocytes showed foot process effacement, vacuolar degeneration, detachment and downregulation of synaptopodin, WT-1, nephrin, and podocalyxin. Mesangial cells showed matrix expansion, increased collagen, mesangiolysis, and, later, sclerosis. Parietal epithelial cells showed vacuolar degeneration and proliferation, whereas endothelial cells were swollen. The severity of the glomerular injury was LMB2 dose dependent. With 1.25 ng/g body wt or more, NEP25 mice developed progressive glomerular damage and died within 2 wk. With 0.625 ng/g body wt of LMB2, NEP25 mice survived >4 wk and developed focal segmental glomerular sclerosis. Thus, the study has established a mouse model of acquired progressive glomerular sclerosis in which onset and severity can be preprogrammed by experimental maneuvers.
                Bookmark

                Author and article information

                Contributors
                Solange.Moll@hcuge.ch
                yasui.yukari16@chugai-pharm.co.jp
                ahmed.b.abed@gmail.com
                muratatks@chugai-pharm.co.jp
                shimada-h@chugai-pharmabody.com
                maedaakr@chugai-pharm.co.jp
                fukushimanos@chugai-pharm.co.jp
                kanamori-m@chugai-pharmabody.com
                sabine.uhles@roche.com
                laura.badi@roche.com
                Thomas.Cagarelli@hcuge.ch
                ivan.formentini@gmail.com
                faye.drawnel@roche.com
                guy.georges@roche.com
                tobias.bergauer@roche.com
                Rodolfo.gasser@roche.com
                rbonfil@nova.edu
                rfridman@med.wayne.edu
                mmoeller@ukaachen.de
                christos.chatziantoniou@upmc.fr
                +41 61 688 68 72 , marco.prunotto@roche.com
                Journal
                J Transl Med
                J Transl Med
                Journal of Translational Medicine
                BioMed Central (London )
                1479-5876
                1 June 2018
                1 June 2018
                2018
                : 16
                : 148
                Affiliations
                [1 ]ISNI 0000 0001 0721 9812, GRID grid.150338.c, Department of Pathology, , University Hospital of Geneva, ; Geneva, Switzerland
                [2 ]GRID grid.418587.7, Research Division, , Chugai Pharmaceutical Co., Ltd, ; Tokyo, Japan
                [3 ]INSERM, UMR S 1155, Hôpital Tenon, 75020 Paris, France
                [4 ]Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
                [5 ]Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany
                [6 ]ISNI 0000 0001 2168 8324, GRID grid.261241.2, Department of Pathology, College of Medical Sciences, , Nova Southeastern University, ; Fort Lauderdale, FL USA
                [7 ]ISNI 0000 0001 1456 7807, GRID grid.254444.7, Department of Pathology, , Wayne State University, ; Detroit, MI USA
                [8 ]ISNI 0000 0001 0728 696X, GRID grid.1957.a, Department of Nephrology and Clinical Immunology, , RWTH University, ; Aachen, Germany
                [9 ]Present Address: Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore
                [10 ]ISNI 0000 0001 1519 6403, GRID grid.418151.8, Present Address: Late Stage, AstraZeneca, ; Göteborgs, Sweden
                [11 ]Present Address: Office of Innovation, Immunology, Infectious Diseases & Ophthalmology (I2O), Roche and Genentech Late Stage Development, 124 Grenzacherstrasse, 4070 Basel, Switzerland
                [12 ]ISNI 0000 0001 2322 4988, GRID grid.8591.5, School of Pharmaceutical Sciences, , University of Geneva, ; Geneva, Switzerland
                Author information
                http://orcid.org/0000-0002-0203-0129
                Article
                1524
                10.1186/s12967-018-1524-5
                5984769
                29859097
                aa3e36f4-2141-4595-88eb-b78968c75941
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 30 April 2018
                : 23 May 2018
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Medicine
                fibrosis,ddr1 inhibition,glomerulosclerosis,ckd
                Medicine
                fibrosis, ddr1 inhibition, glomerulosclerosis, ckd

                Comments

                Comment on this article